Top

Published in:

Open Access 01-12-2022 | Colon Cancer | Review

Luteolin: a flavonoid with a multifaceted anticancer potential

Authors: Parteek Prasher, Mousmee Sharma, Sachin Kumar Singh, Monica Gulati, Dinesh Kumar Chellappan, Flavia Zacconi, Gabriele De Rubis, Gaurav Gupta, Javad Sharifi-Rad, William C. Cho, Kamal Dua

Published in: Cancer Cell International | Issue 1/2022

Abstract

Therapeutic effect of phytochemicals has been emphasized in the traditional medicine owing to the presence of bioactive molecules, such as polyphenols. Luteolin is a flavone belonging to the flavonoid class of polyphenolic phytochemicals with healing effect on hypertension, inflammatory disorders, and cancer due to its action as pro-oxidants and antioxidants. The anticancer profile of luteolin is of interest due to the toxic effect of contemporary chemotherapy paradigm, leading to the pressing need for the development and identification of physiologically benevolent anticancer agents and molecules. Luteolin exerts anticancer activity by downregulation of key regulatory pathways associated with oncogenesis, in addition to the induction of oxidative stress, cell cycle arrest, upregulation of apoptotic genes, and inhibition of cell proliferation and angiogenesis in cancer cells. In this review, we discuss about the anticancer profile of luteolin.

Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updat. 2021;59:100796.CrossRef

George BP, Chandran R, Abrahamse H. Role of Phytochemicals in Cancer Chemoprevention: insights. Antioxidants 2021;10(9):1455.CrossRef

Ashrafizadeh M, Ahmadi Z, Farkhondeh T, Samarghandian S. Autophagy regulation using luteolin: new insight into its anti-tumor activity. Cancer Cell Int. 2020;20(1):537.CrossRef

Chen HI, Hu WS, Hung MY, Ou HC, Huang SH, Hsu PT, Day CH, Lin KH, Viswanadha VP, Kuo WW, et al. Protective effects of luteolin against oxidative stress and mitochondrial dysfunction in endothelial cells. Nutr Metab Cardiovasc Dis. 2020;30(6):1032–43.CrossRef

Imran M, Rauf A, Abu-Izneid T, Nadeem M, Shariati MA, Khan IA, Imran A, Orhan IE, Rizwan M, Atif M, et al. Luteolin, a flavonoid, as an anticancer agent: a review. Biomed Pharmacother. 2019;112:108612.CrossRef

Tan X, Yang Y, Xu J, Zhang P, Deng R, Mao Y, He J, Chen Y, Zhang Y, Ding J, et al. Luteolin exerts Neuroprotection via Modulation of the p62/Keap1/Nrf2 pathway in Intracerebral Hemorrhage. Front Pharmacol. 2019;10:1551.CrossRef

Kang KA, Piao MJ, Ryu YS, Hyun YJ, Park JE, Shilnikova K, Zhen AX, Kang HK, Koh YS, Jeong YJ, et al. Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells. Int J Oncol. 2017;51(4):1169–78.CrossRef

Raj Rai S, Bhattacharyya C, Sarkar A, Chakraborty S, Sircar E, Dutta S, Sengupta R. Glutathione: role in Oxidative/Nitrosative stress, antioxidant defense, and treatments. ChemistrySelect. 2021;6(18):4566–90.CrossRef

Yue J, López JM. Understanding MAPK signaling pathways in apoptosis. Int J Mol Sci. 2020;21(7):2346.CrossRef

10.

Zhang Q, Yang J, Wang J. Modulatory effect of luteolin on redox homeostasis and inflammatory cytokines in a mouse model of liver cancer. Oncol Lett. 2016;12(6):4767–72.CrossRef

11.

Selvaraj S, Krishnaswamy S, Devashya V, Sethuraman S, Krishnan UM. Flavonoid-metal ion complexes: a novel class of therapeutic agents. Med Res Rev. 2014;34(4):677–702.CrossRef

12.

Dong H, Yang X, He J, Cai S, Xiao K, Zhu L. Enhanced antioxidant activity, antibacterial activity and hypoglycemic effect of luteolin by complexation with manganese(ii) and its inhibition kinetics on xanthine oxidase. RSC Adv. 2017;7(84):53385–95.CrossRef

13.

Cantu-Medellin N, Kelley EE. Xanthine oxidoreductase-catalyzed reactive species generation: a process in critical need of reevaluation. Redox Biol. 2013;1(1):353–8.CrossRef

14.

Yan M, Liu Z, Yang H, Li C, Chen H, Liu Y, Zhao M, Zhu Y. Luteolin decreases the UVA–induced autophagy of human skin fibroblasts by scavenging ROS. Mol Med Rep. 2016;14(3):1986–92.CrossRef

15.

Ju W, Wang X, Shi H, Chen W, Belinsky SA, Lin Y. A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappab pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol. 2007;71(5):1381–8.CrossRef

16.

Li G, Zhou J, Sun M, Cen J, Xu J. Role of luteolin extracted from Clerodendrum cyrtophyllum Turcz leaves in protecting HepG2 cells from TBHP-induced oxidative stress and its cytotoxicity, genotoxicity. J Funct Foods. 2020;74:104196.CrossRef

17.

Nazari QA, Kume T, Takada-Takatori Y, Izumi Y, Akaike A. Protective effect of luteolin on an oxidative-stress model induced by microinjection of sodium nitroprusside in mice. J Pharmacol Sci. 2013;122(2):109–17.CrossRef

18.

Lo S, Leung E, Fedrizzi B, Barker D. Syntheses of mono-acylated luteolin derivatives, evaluation of their antiproliferative and radical scavenging activities and implications on their oral bioavailability. Sci Rep. 2021;11(1):12595.CrossRef

19.

Bai J, Li Y, Zhang G. Cell cycle regulation and anticancer drug discovery. Cancer Biol Med. 2017;14(4):348–62.CrossRef

20.

Huang L, Jin K, Lan H. Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase. Oncol Lett. 2019;17(4):3842–50.

21.

Park SH, Ham S, Kwon TH, Kim MS, Lee DH, Kang JW, Oh SR, Yoon DY. Luteolin induces cell cycle arrest and apoptosis through extrinsic and intrinsic signaling pathways in MCF-7 breast cancer cells. J Environ Pathol Toxicol Oncol. 2014;33(3):219–31.CrossRef

22.

Raina R, Pramodh S, Rais N, Haque S, Shafarin J, Bajbouj K, Hamad M, Hussain A. Luteolin inhibits proliferation, triggers apoptosis and modulates Akt/mTOR and MAP kinase pathways in HeLa cells. Oncol Lett. 2021;21(3):192.CrossRef

23.

Cai X, Ye T, Liu C, Lu W, Lu M, Zhang J, Wang M, Cao P. Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells. Toxicol In Vitro. 2011;25(7):1385–91.CrossRef

24.

Chen Z, Zhang B, Gao F, Shi R. Modulation of G(2)/M cell cycle arrest and apoptosis by luteolin in human colon cancer cells and xenografts. Oncol Lett. 2018;15(2):1559–65.

25.

Chang J, Hsu Y, Kuo P, Kuo Y, Chiang L, Lin C. Increase of Bax/ Bcl-XL ratio and arrest of cell cycle by luteolin in immortalized human hepatoma cell line. Life Sci. 2005;76(16):1883–93.CrossRef

26.

Choi EJ, Bae SM, Ahn WS. Antiproliferative effects of quercetin through cell cycle arrest and apoptosis in human breast cancer MDA-MB-453 cells. Arch Pharm Res. 2008;31(10):1281–5.CrossRef

27.

George VC, Naveen Kumar DR, Suresh PK, Kumar S, Kumar RA. Comparative studies to evaluate relative in vitro potency of luteolin in inducing cell cycle arrest and apoptosis in HaCaT and A375 cells. Asian Pac J Cancer Prev. 2013;14(2):631–7.CrossRef

28.

Yoo HS, Won SB, Kwon YH. Luteolin induces apoptosis and autophagy in HCT116 Colon cancer cells via p53-Dependent pathway. Nutr Cancer. 2022;74(2):677–86.CrossRef

29.

Lee Y, Kwon YH. Regulation of apoptosis and autophagy by luteolin in human hepatocellular cancer Hep3B cells. Biochem Biophys Res Commun. 2019;517(4):617–22.CrossRef

30.

Lee HS, Park BS, Kang HM, Kim JH, Shin SH, Kim IR. Role of Luteolin-Induced apoptosis and autophagy in human glioblastoma cell lines. Medicina. 2021;57(9):879.CrossRef

31.

Cao Z, Zhang H, Cai X, Fang W, Chai D, Wen Y, Chen H, Chu F, Zhang Y. Luteolin promotes cell apoptosis by inducing Autophagy in Hepatocellular Carcinoma. Cell Physiol Biochem. 2017;43(5):1803–12.CrossRef

32.

Nazim UM, Park SY. Luteolin sensitizes human liver cancer cells to TRAIL–induced apoptosis via autophagy and JNK–mediated death receptor 5 upregulation. Int J Oncol. 2019;54(2):665–72.

33.

Pandurangan AK, Kumar SA, Dharmalingam P, Ganapasam S. Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: involvement of iNOS and COX-2. Pharmacogn Mag. 2014;10(Suppl 2):306–10.

34.

Pandurangan AK, Ananda Sadagopan SK, Dharmalingam P, Ganapasam S. Luteolin, a bioflavonoid inhibits azoxymethane-induced colorectal cancer through activation of Nrf2 signaling. Toxicol Mech Methods. 2014;24(1):13–20.CrossRef

35.

Pandurangan AK, Dharmalingam P, Sadagopan SK, Ganapasam S. Luteolin inhibits matrix metalloproteinase 9 and 2 in azoxymethane-induced colon carcinogenesis. Hum Exp Toxicol. 2014;33(11):1176–85.CrossRef

36.

Lim DY, Cho HJ, Kim J, Nho CW, Lee KW, Park JH. Luteolin decreases IGF-II production and downregulates insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells. BMC Gastroenterol. 2012;12:9.CrossRef

37.

Potočnjak I, Šimić L, Gobin I, Vukelić I, Domitrović R. Antitumor activity of luteolin in human colon cancer SW620 cells is mediated by the ERK/FOXO3a signaling pathway. Toxicol In Vitro. 2020;66:104852.CrossRef

38.

Kang KA, Piao MJ, Hyun YJ, Zhen AX, Cho SJ, Ahn MJ, Yi JM, Hyun JW. Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells. Exp Mol Med. 2019;51(4):1–14.CrossRef

39.

Yao Q, Luo Y, Sun L, Wang H, Li W. Luteolin suppressed growth of colon tumor via inflammation, oxidative stress, and NLRP3/IL-1β signal axis. Pharmacognosy Magazine. 2022;18(78):494–501.

40.

Zuo T, Yue Y, Wang X, Li H, Yan S. Luteolin Relieved DSS-Induced colitis in mice via HMGB1-TLR-NF-κB signaling pathway. Inflammation. 2021;44(2):570–9.CrossRef

41.

Aromokeye R, Si H. Combined Curcumin and Luteolin synergistically inhibit Colon Cancer Associated with Notch1 and TGF-β signaling pathways in cultured cells and xenograft mice. Cancers. 2022;14(12):3001.CrossRef

42.

Zuo Q, Wu R, Xiao X, Yang C, Yang Y, Wang C, Lin L, Kong AN. The dietary flavone luteolin epigenetically activates the Nrf2 pathway and blocks cell transformation in human colorectal cancer HCT116 cells. J Cell Biochem. 2018;119(11):9573–82.CrossRef

43.

Kollur SP, Prasad SK, Pradeep S, Veerapur R, Patil SS, Amachawadi RG, Lamraoui SRP, Al-Kheraif G, Elgorban AAAM, et al. Luteolin-fabricated ZnO nanostructures showed PLK-1 mediated Anti-Breast Cancer Activity. Biomolecules. 2021;11(3):385.CrossRef

44.

Wu HT, Lin J, Liu YE, Chen HF, Hsu KW, Lin SH, Peng KY, Lin KJ, Hsieh CC, Chen DR. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway. Phytomedicine. 2021;81:153437.CrossRef

45.

Gao G, Ge R, Li Y, Liu S. Luteolin exhibits anti-breast cancer property through up-regulating miR-203. Artif Cells Nanomed Biotechnol. 2019;47(1):3265–71.CrossRef

46.

Lin D, Kuang G, Wan J, Zhang X, Li H, Gong X, Li H. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression. Oncol Rep. 2017;37(2):895–902.CrossRef

47.

Lee J, Park SH, Lee J, Chun H, Choi MK, Yoon JH, Pham TH, Kim KH, Kwon T, Ryu HW, et al. Differential effects of luteolin and its glycosides on invasion and apoptosis in MDA-MB-231 triple-negative breast cancer cells. Excli J. 2019;18:750–63.

48.

Cao D, Zhu GY, Lu Y, Yang A, Chen D, Huang HJ, Peng SX, Chen LW, Li YW. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. Biomed Pharmacother. 2020;129:110462.CrossRef

49.

Sun DW, Zhang HD, Mao L, Mao CF, Chen W, Cui M, Ma R, Cao HX, Jing CW, Wang Z, et al. Luteolin inhibits breast Cancer Development and Progression in Vitro and in vivo by suppressing Notch Signaling and regulating MiRNAs. Cell Physiol Biochem. 2015;37(5):1693–711.CrossRef

50.

Dong X, Zhang J, Yang F, Wu J, Cai R, Wang T, Zhang J. Effect of luteolin on the methylation status of the OPCML gene and cell growth in breast cancer cells. Exp Ther Med. 2018;16(4):3186–94.

51.

Cook MT, Liang Y, Besch-Williford C, Hyder SM. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. Breast Cancer 2017;9:9–19.

52.

Tsai KJ, Tsai HY, Tsai CC, Chen TY, Hsieh TH, Chen CL, Mbuyisa L, Huang YB, Lin MW. Luteolin inhibits breast Cancer stemness and enhances chemosensitivity through the Nrf2-Mediated pathway. Molecules. 2021;26(21):6452.CrossRef

53.

Masraksa W, Tanasawet S, Hutamekalin P, Wongtawatchai T, Sukketsiri W. Luteolin attenuates migration and invasion of lung cancer cells via suppressing focal adhesion kinase and non-receptor tyrosine kinase signaling pathway. Nutr Res Pract. 2020;14(2):127–33.CrossRef

54.

Yu Q, Zhang M, Ying Q, Xie X, Yue S, Tong B, Wei Q, Bai Z, Ma L. Decrease of AIM2 mediated by luteolin contributes to non-small cell lung cancer treatment. Cell Death Dis. 2019;10(3):218.CrossRef

55.

Jiang ZB, Wang WJ, Xu C, Xie YJ, Wang XR, Zhang YZ, Huang JM, Huang M, Xie C, Liu P, et al. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Lett. 2021;515:36–48.CrossRef

56.

Jiang ZQ, Li MH, Qin YM, Jiang HY, Zhang X, Wu MH. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p. Int J Mol Sci. 2018;19(2):447.CrossRef

57.

Zhang M, Wang R, Tian J, Song M, Zhao R, Liu K, Zhu F, Shim JH, Dong Z, Lee MH. Targeting LIMK1 with luteolin inhibits the growth of lung cancer in vitro and in vivo. J Cell Mol Med. 2021;25(12):5560–71.CrossRef

58.

Hong Z, Cao X, Li N, Zhang Y, Lan L, Zhou Y, Pan X, Shen L, Yin Z, Luo L. Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance. Br J Pharmacol. 2014;171(11):2842–53.CrossRef

59.

Zhao Y, Yang G, Ren D, Zhang X, Yin Q, Sun X. Luteolin suppresses growth and migration of human lung cancer cells. Mol Biol Rep. 2011;38(2):1115–9.CrossRef

60.

Chen W, Weng S, Zhang F, Allen S, Li X, Bao L, Lam RH, Macoska JA, Merajver SD, Fu J. Nanoroughened surfaces for efficient capture of circulating tumor cells without using capture antibodies. ACS Nano. 2013;7(1):566–75.CrossRef

61.

Zhou YS, Cui Y, Zheng JX, Quan YQ, Wu SX, Xu H, Han Y. Luteolin relieves lung cancer-induced bone pain by inhibiting NLRP3 inflammasomes and glial activation in the spinal dorsal horn in mice. Phytomedicine. 2022;96:153910.CrossRef

62.

Seo Y, Ryu K, Park J, Jeon DK, Jo S, Lee HK, Namkung W. Inhibition of ANO1 by luteolin and its cytotoxicity in human prostate cancer PC-3 cells. PLoS ONE. 2017;12(3):e0174935.CrossRef

63.

Zhou Q, Yan B, Hu X, Li XB, Zhang J, Fang J. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol Cancer Ther. 2009;8(6):1684–91.CrossRef

64.

Han K, Lang T, Zhang Z, Zhang Y, Sun Y, Shen Z, Beuerman RW, Zhou L, Min D. Luteolin attenuates wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics. Sci Rep. 2018;8(1):8537.CrossRef

65.

Pratheeshkumar P, Son YO, Budhraja A, Wang X, Ding S, Wang L, Hitron A, Lee JC, Kim D, Divya SP, et al. Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS ONE. 2012;7(12):e52279.CrossRef

66.

Han K, Meng W, Zhang JJ, Zhou Y, Wang YL, Su Y, Lin SC, Gan ZH, Sun YN, Min DL. Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301. Onco Targets Ther. 2016;9:3085–94.CrossRef

67.

Sakurai MA, Ozaki Y, Okuzaki D, Naito Y, Sasakura T, Okamoto A, Tabara H, Inoue T, Hagiyama M, Ito A, et al. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630. PLoS ONE. 2014;9(6):e100124.CrossRef

68.

Naiki-Ito A, Naiki T, Kato H, Iida K, Etani T, Nagayasu Y, Suzuki S, Yamashita Y, Inaguma S, Onishi M, et al. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer. Carcinogenesis. 2019;41(8):1145–57.CrossRef

Title: Luteolin: a flavonoid with a multifaceted anticancer potential
Authors: Parteek Prasher
Mousmee Sharma
Sachin Kumar Singh
Monica Gulati
Dinesh Kumar Chellappan
Flavia Zacconi
Gabriele De Rubis
Gaurav Gupta
Javad Sharifi-Rad
William C. Cho
Kamal Dua
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Colon Cancer
Colon Cancer
Published in: Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-022-02808-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Rcl1 suppresses tumor progression of hepatocellular carcinoma: a comprehensive analysis of bioinformatics and in vitro experiments

Periostin: biology and function in cancer

HOXC6 impacts epithelial-mesenchymal transition and the immune microenvironment through gene transcription in gliomas

High AKAP8L expression predicts poor prognosis in esophageal squamous cell carcinoma

Cirsiliol regulates mitophagy in colon cancer cells via STAT3 signaling

Activation of embryonic/germ cell-like axis links poor outcomes of gliomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer